Drug Development
ACR16 receives orphan drug designation in the U.S. for Huntington disease
Published in Drug Week, February 10th, 2006
Huntington disease is a hereditary neurodegenerative disorder with large unmet medical needs. ACR16 is a novel dopaminergic stabilizer with potential to treat the symptoms associated with the disorder. It is currently in phase II clinical trials.
Orphan drug status is granted by the OOPD to promote development of drugs to treat rare diseases or conditions. Orphan drug designation in the U.S. may provide several benefits, including protocol...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-02-10)
More Articles from Drug Week
- Chlamydia Pneumonia
A novel phenoxazine derivative may be useful for controlling Chlamydia pneumoniae - Clarithromycin
Non-irradiated mice fared better with therapy for Bacillus anthracis Sterne infection - Drug Development
Approval granted to commence phase III study of Androxal for testosterone deficiency - Gene Expression
Neuropeptide gene expression in response to acute drug challenge may include modulation of behavioral effects - Acute Bacterial Sinusitis
Biopharma company submits NDA for Orapem to treat respiratory tract and skin infections - Addiction Medicine
Interaction reported between expression of D-serine-related enzymes and opioid receptor activation - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
